Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. - Wikidata - wikimedia - TriplyDB

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

http://www.wikidata.org/entity/Q35161892

about

Current status of biomarker research in neurology Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease Emerging candidate biomarkers for Parkinson's disease: a review Predicting cognitive decline in Parkinson's disease: can we ask the genes?Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.Plasma apolipoprotein A1 as a biomarker for Parkinson disease Targeted discovery and validation of plasma biomarkers of Parkinson's disease.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Blood-based biomarkers for Parkinson's disease Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer's disease Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.Lewy body dementias.Ameliorative effects of a combination of baicalin, jasminoidin and cholic acid on ibotenic acid-induced dementia model in rats.Unbiased approaches to biomarker discovery in neurodegenerative diseases SMA-MAP: a plasma protein panel for spinal muscular atrophy Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel.Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease.Plasma epidermal growth factor decreased in the early stage of Parkinson's disease.Genetic influences on cognitive decline in Parkinson's disease.Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease.Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes.Converging mediators from immune and trophic pathways to identify Parkinson disease dementia.The NINDS Parkinson's disease biomarkers program.Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease Parkinson's disease biomarkers: resources for discovery and validation.A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults.A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease.TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.Biomarkers for trials of neuroprotection in Parkinson's disease.Is there a need to redefine Parkinson's disease?Recent developments in biomarkers in Parkinson disease What can biomarkers tell us about cognition in Parkinson's disease?Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging.

P2860

Q26744505-817F95B1-3F59-403B-98A2-F2ABDAE2DA73 Q26746174-B370068B-A5D9-4543-9AB3-97DBCCEAB476 Q27015018-ADD2DE5D-3234-4191-97CD-B28CBF758DB5 Q27025463-0D5D09EA-BBDD-4E96-BBA1-A86CB8C7F64C Q27333275-4B15EDD4-9CB1-477B-A3A8-A50C310EEBBE Q27686837-587E83C2-F940-4D6B-A31E-C5FB5FC3B7DB Q28550937-3F2FCD1F-20E2-4B6D-9AEC-C62DE8D77D6A Q28552902-E590143E-B188-4171-81C1-473FF7CEE8EC Q30544056-D94855A6-4680-4E51-87F1-AC2601FA1D6B Q30544798-65E53F58-85A3-4677-ABD5-928BCEA10F49 Q30597182-9F6BDD97-9F0E-4013-BFFF-B0C5406992DD Q31097119-F9901B79-AA70-4486-8F51-31EA9B3F5BD3 Q33804255-D1659111-7C45-42F2-9AC8-5B69721B2F04 Q33867548-CC7619CF-46DB-4CEC-9FCD-05856ECB1CD0 Q34438204-B27224A0-E374-480A-A66F-4FD25C21C9BA Q34502646-8033F834-A55D-40B5-B443-F0D8AABFC600 Q34599205-C2328DFF-B7F9-485F-BECD-352AC508D145 Q34625918-D3B66153-7988-49FE-8098-C383AA4BABCD Q34658131-0E75120F-B9BE-42FA-ABF3-8331DF0D8DD1 Q34875967-694624A2-6036-4B5E-A92E-4D00DD5EEF5F Q35096897-BC7FF393-6A53-4A77-BDD8-B8E676AF5B59 Q35129144-CF24794D-A7E6-46D1-A1C6-1A6FAB5FF733 Q35636853-20A63494-F90B-45E0-808E-13D77FA720CC Q35881786-9753EC94-E957-4894-A07C-1E131FD858F4 Q36183810-280133EE-58B0-4D68-8330-2117E2D015A5 Q36276511-ACAEF24D-1BA6-4827-8486-2F899E9AB784 Q36517459-61E199CC-3864-44B0-8B7D-660FB08CE84B Q36521242-5EAF73EB-383D-4E98-AC30-73E26C327F75 Q36777618-BFB8BBE9-EC73-4A4F-9882-2261A65A5313 Q36891717-A3B6F55D-04FA-4226-B787-6FA69068F9CC Q37379512-4C120BE0-714C-4C33-92AD-176105A41C09 Q37564505-AEA00241-F17B-4D6A-B1C5-E19524AE28A0 Q37600861-A1C3CAA0-88F2-4743-94FA-74CAA8CC46B3 Q37688034-5C612902-7519-44B2-9051-AF0370D9D5AE Q37730909-2C5F58BB-4E91-42EC-9931-2BDE4B5DC62E Q38038544-3B67D199-0012-4B47-977E-847768962EBE Q38110209-DC7629A6-7A96-468B-A45D-5E673DED54E7 Q38119095-51F99C65-C739-4F5F-AFB5-40D44DA4C3F4 Q38206497-9F90BD09-804F-4BFD-AF8C-E70E993D831A Q38315590-DB73117A-D7E2-4360-ABC5-F6755348EB23

P2860

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

http://www.wikidata.org/entity/Q35161892

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

@ast

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

@en

type

label

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

@ast

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

@en

prefLabel

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

@ast

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

@en

P1433

Q35161892-948991BD-CD30-46CE-A25F-2FB64B38EBD2

P1476

Q35161892-03243A03-9A43-4E75-8E11-C56DB808BB8E

P2093

Q35161892-00B79FA3-3E0C-4B00-A4EC-9B7463A2695D

Q35161892-0431EAA8-ADCF-49AF-AD09-55557DFCAFF3

Q35161892-1CB5C5B9-B37F-430A-9108-178AE721E24D

Q35161892-380F3D9C-A9A1-473B-B230-FBC2DCEDC4B1

Q35161892-AAFC35CF-6048-4145-B0CC-1788637F6341

Q35161892-C01688EE-9C73-4A45-8994-0FD0E3503E57

Q35161892-C3D732FF-44C8-4696-A783-912726A8C3E6

Q35161892-CB74958E-D3C1-4F3A-8247-59F7EEBDA359

Q35161892-DB44B87E-1430-4FC9-B928-0F35D6E28C01

Q35161892-DE858F69-BD30-4FB3-A85B-C6A18F466FC3

P2860

Q35161892-07EE6153-9E5E-4D05-8EC8-26CDC71355D4

Q35161892-1F9912A3-42A7-4E8E-AB69-CF2CB5C334D0

Q35161892-293FE6CB-0E15-48BF-8B5F-9B90948F9C9D

Q35161892-296BA0C6-CE02-49B4-8542-73345CF4B22C

Q35161892-36CC627E-714E-41C8-8F71-C4431F6CA479

Q35161892-4C9924CE-D642-4917-9E8A-980A8E554947

Q35161892-4CFB640F-DF8A-496B-AC12-EE2BA430FE9A

Q35161892-5650B7E3-BAAA-4CB9-9879-314385013C74

Q35161892-783A2AD8-BBE6-4E57-A481-F18293D6A814

Q35161892-8055C890-9CFB-4C89-8937-A7710F40385F

P304

Q35161892-8E459201-B805-4743-BCC8-7B1B8E8E177C

P31

Q35161892-890CA167-57BA-4277-BB1F-7FA2FC8F7253

P356

Q35161892-47406F71-D454-450E-8FD2-21537F9D18E2

P433

Q35161892-ABD644DB-FB44-4305-8380-F5AFB1F4A100

P478

Q35161892-53DD30D3-8DDD-4372-A0A6-FEE77472663E

P50

Q35161892-14F03401-FE03-42C7-AEA0-66B35C2C9A0B

Q35161892-3940D616-206F-4420-BCCE-0D6C8A583884

Q35161892-6DD3FA02-7ADC-4F88-95FC-6820ECA0A153

Q35161892-90881370-7426-47BC-92F9-480F27AC5C05

Q35161892-D62FF942-A9E2-4BCC-A4A6-CC8759AF5F83

P577

Q35161892-492502BD-A6D9-40F0-8E25-580285847A6F

P5875

Q35161892-34F70E92-2EBD-4D69-9799-480A88879992

P698

Q35161892-E6987C39-B32A-4DBA-853E-F72F341B6902

P921

Q35161892-49B5019C-4898-4DDA-976B-D470996C6C9A

P932

Q35161892-C0AFFD5E-EAD3-4A14-8BA2-49FDECD7BF47

P356

P1433

Annals of Neurology

P1476

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

@en

P2093

Alice S Chen-Plotkin

http://www.w3.org/2001/XMLSchema#string

Christopher M Clark

http://www.w3.org/2001/XMLSchema#string

Holly Soares

http://www.w3.org/2001/XMLSchema#string

Howard I Hurtig

http://www.w3.org/2001/XMLSchema#string

Lauren Elman

http://www.w3.org/2001/XMLSchema#string

Leo McCluskey

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Rachel Goldmann Gross

http://www.w3.org/2001/XMLSchema#string

Sharon X Xie

http://www.w3.org/2001/XMLSchema#string

Virginia M-Y Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models

Staging of brain pathology related to sporadic Parkinson's disease

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) regulates survival of midbrain dopaminergic neurons

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Normative data for the Mattis Dementia Rating Scale.

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment

Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.

Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

P304

655-663

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.22271

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

John Q. Trojanowski

Steven E. Arnold

Daniel Weintraub

Murray Grossman

Andrew Siderowf

P577

2010-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51077160

http://www.w3.org/2001/XMLSchema#string

P698

21520231

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3155276

http://www.w3.org/2001/XMLSchema#string